## Prescriber Criteria Form

## Scemblix 2025 PA Fax 5048-A v3 040125.docx Scemblix (asciminib) Coverage Determination

This fax machine is located in a secure location as required by HIPAA regulations.

Complete/review information, sign and date. Fax signed forms to CVS Caremark at **1-855-633-7673.** Please contact CVS Caremark at 1-866-785-5714 with questions regarding the prior authorization process. When conditions are met, we will authorize the coverage of Scemblix (asciminib).

Drug Name:

Scemblix (asciminib)			
Patient Name:			
Patient ID:			
Patient DOB:	Patient Phone:		
Prescriber Name:	<u>'</u>		
Prescriber Address:			
City:	State:	Zip:	
Prescriber Phone:	Prescriber Fax:		
Diagnosis:	ICD Code(s):		

Plea	se circle the appropriate answer for each question.		
1	Does the patient have a diagnosis of chronic phase chronic myeloid leukemia (CML)? [If no, then skip to question 8.]	Yes	No
2	Was the diagnosis confirmed by detection of the Philadelphia chromosome or BCR-ABL gene? [If no, then no further questions.]	Yes	No
3	Is the patient positive for the T315I mutation? [If yes, then skip to question 7.]	Yes	No
4	Does the patient have newly diagnosed chronic myeloid leukemia (CML)? [If no, then skip to question 6.]	Yes	No
5	Has the patient experienced resistance or intolerance to at least one of the following: a) imatinib, b) dasatinib, c) nilotinib? [If yes, then skip to question 7.] [If no, then no further questions.]	Yes	No
6	Does the patient have previously treated chronic myeloid leukemia (CML) and at least one of the prior treatments was imatinib, dasatinib, or nilotinib? [If no, then no further questions.]	Yes	No

Prescri	ber (or Authorized) Signature: Date:		
, ,	ing this form, I attest that the information provided is accurate and true as of this date and tentation supporting this information is available for review if requested by the health plan.	hat the	
Comme	ents:		
9	Is the disease in the chronic phase or blast phase?	Yes	No
	[If no, then no further questions.]		
	eosinophilia and ABL1 rearrangement?		
8	Does the patient have a diagnosis of myeloid and/or lymphoid neoplasms with	Yes	No
	[No further questions.]		
7	Is the patient negative for both of the following mutations: A) A337T, B) P465S?	Yes	No